Research News
Research News
-
The Second Berlin Patient
The second Berlin Patient HIV cure opens up new possibilities and amfAR researchers are working to make this strategy an accessible, affordable one.
-
Six Researchers, One Goal
New amfAR grants totaling more than $2.5 million support strategies to cure HIV, from immunotherapy to latency-reversing and anti-cancer agents.
-
Inhibiting HIV by Host Cell Targeting Strategies
-
Beyond Stem Cell Transplantation?
amfAR awards grants to researchers—Drs. Jonah Sacha, Elena Herrera-Carrillo, and Alexander Pasternak—who are testing innovative HIV cure strategies.
-
Predicting Changes in the HIV Reservoir
Researchers zero in on a marker, sugar-protein Galectin-9, that might be able to target HIV persistence, the main barrier to a cure for people living with the virus.
-
A Possible New Avenue to a Cure
A study of the Geneva patient, cured of HIV via a transplant with cells susceptible to infection, opens up new possibilities of eradicating the virus.
-
Lenacapavir Looks to Revolutionize HIV Prevention
PURPOSE 2 study results show that a twice-yearly injectable HIV antiretroviral, lenacapavir, is highly effective as PrEP among MSM, transgender women and men who have sex with men, and others.
-
Researchers Identify a Novel Cell Protein that Can Control HIV Growth
Researchers have discovered a cell protein that can restrict the late phases of HIV replication as well as that of pox viruses.
-
Curing HIV—How Far Have We Come?
It can be hard to keep track of the various cases of HIV having been cured or controlled in the absence of antiretroviral therapy. amfAR has put together a helpful summary.
-
Next-Generation PrEP
PURPOSE 1 trial results show that a twice-yearly injectable—lenacapavir for PrEP—is 100% effective at preventing HIV infection among cisgender women and girls.
-
Daily Updates from the 2024 International AIDS Conference
Daily updates of sessions at AIDS 2024 cover research on curing HIV, HIV care, and AIDS policy from amfAR and others.
-
The Second Berlin Patient
A seventh person, the second Berlin Patient, has been cured of HIV, providing new evidence that a stem cell transplant with a CCR5 gene mutation might not be the only path to a cure.
-
amfAR Greenlights New HIV Cure Studies with Grants Totaling $1.2 Million
amfAR grants totaling $1.2 million allow three researchers to test the ability of a pair of cancer drugs and broadly neutralizing antibodies to attack HIV reservoirs, the main barrier to a cure.
-
Forming HIV Reservoirs, Informing Cure Strategies
Researchers, led by amfAR grantee Dr. Edward Kankaka, gain new insight into the initial formation of HIV reservoirs, the main barrier to an HIV cure.
-
amfAR at AIDS 2024: Presentations, Meetings, and Workshops
A full listing of amfAR-related presentations and sessions at AIDS 2024